The pharmaceutical industry in Japan holds great potential for growth. Having a strong research and development capability for new drugs, the contribution of the Japanese pharmaceutical industry in promoting global public health is large. Much is expected of Japan as a strategic pharmaceutical industry.
The Japanese pharmaceutical industry has evolved dramatically over the past decade and is continuing to adapt to the evolving demands of the international healthcare markets. Complementing other pharmaceutical markets in Asia, Japan has a well-established pharmaceutical industry with high drug quality standards estimated to be worth US$ 87 billion by 2014.
A combination of major drug patent expiries before 2012, rapidly ageing demographic, wide-ranging government initiatives to reduce healthcare spending and comparatively high reimbursement prices are making the generic drug sector in Japan increasingly attractive to foreign manufacturers looking for a large, relatively untapped and receptive market. Changing demographics in Japan have prompted its government to create legislation that supports foreign investment into the pharmaceutical industry
Japanese society has one of the highest levels of life expectancy and there is a big demand for medicines in the elder care sector. In this regard, regenerative medicine achieved outstanding results and has drawn particular attention after Kyoto University Professor, Shinya Yamanaka, won the Nobel Prize last year for his advanced research on induced pluripotent stem cells.
Additionally, as part of the Prime Minister Abe’s plan, a combination of big government spending and an aggressive central bank asset buying programme have just been approved to meet an ambitious two per cent inflation target in the next two years. This has given companies an incentive to spend and invest in this stimulating economy.
At the same time generic market size is forecast to reach 1080 billion yen by 2014 and expand to 1740 billion in 2020, accounting for a 30 per cent market share. Pharmaceutical companies are actively looking for international partners to help them boost capacity and speed up approval of new drugs. The generics and biosimilars markets are now burgeoning in order to reduce public health costs, resulting in immense growth potential.
Japan’s APIs and intermediates producers, including pharmaceutical manufacturers who develop these products internally, are always on the lookout for new technologies for enhancing quality control, safety assurance, and increasing production efficiency.
The sector has evolved dramatically over the past decade. Given the massive development costs that it faces, the pharmaceutical industry in Japan is undergoing changes, such as restructuring through mergers and acquisitions, and as a result the business environment in which pharmaceutical companies find themselves is transforming rapidly. Japan's pharmaceutical industry is in the midst of major changes.
In this context CPhI Japan 2013, the international fair on chemical and pharmaceutical ingredients taking place at the Tokyo Big Sight exhibition centre, Japan from April 24 to 26 is of special significance to Japan as well as the global pharma industry. Running parallel to other international pharma events like ICSE, P-MEC, and BioPh, the event is considered to be a vital business platform for the 14,000 pharma professionals and 450 exhibitors expected from 29 countries.
CPhI Japan 2013 is the industry’s premier business platform where pharma professionals, exhibitors and key decision makers from across the world gather to do business in this region. The event is a unique opportunity to move into the Japanese market and meet industry leaders in person and to build strategic partnerships.
By attending the event participants will get an opportunity to meet leading companies and their representatives in person, all under one roof. This would provide an excellent chance to explore new business opportunities, expand network, meet other pharmaceutical professionals and build partnerships. The event would gather all major suppliers of pharmaceutical ingredients, the latest machinery & technology, outsourcing solutions and bio-solution at the same venue.
ICSE Japan connects the pharmaceutical community with diverse outsourcing solutions such as: clinical trials, contract manufacturing, contract research, packaging, logistics or analytical services.
Held alongside CPhI Japan, ICSE attracts international exhibitors who are keen to capitalise on the benefits of doing business in Japan. Besides contract manufacturing and contract research, other main services provided are packaging, clinical trials, laboratory services, drug discovery and marketing services.
P-MEC Japan is dedicated to machinery & technology for R&D and the pharma manufacturing ingredients process. It will focus on advanced technology to enhance areas like quality control, safety assurance and increased production efficiency.
Returning for the third time BioPh Japan will gather key players within the biotechnology and related fields to drive innovation and development in the industry.
BioPh Japan is returning for its third year, gathering the key players within the biotechnology and related fields to drive innovation and development in the industry. With the great growth predictions of the Japanese biopharmaceutical sector, BioPh Japan serves as the vital gateway to this booming market.
Biotechnology-based drugs are anticipated to be one of the key drivers of the pharmaceutical market and this is reflected in the growing number biotechnology based drugs among newly approved medicines.
BioPh brings bio solutions to CPhI Japan and is for companies and organisations involved in the research and development of new treatment methods arising from biotechnical processes or which are derived from, or use live organisms.
The Japanese pharmaceutical manufacturers have been eager to catch up the US and European players in the bio field by investing and cooperating with bio ventures and universities. The government has also been investing in infrastructure development such as bio industrial cluster projects and setting up support programs for bio ventures and universities in order to enhance Japan’s bio pharma industry.
Added this year, Pharmatec Japan will be focusing on 'Drug Packaging and Delivery Technology' for the pharmaceutical, biopharmaceutical, veterinary and medical industries in Japan.
This is a quality event for "Drug Packaging and Delivery Technology" for the pharmaceutical, biopharmaceutical, veterinary and medical industries, generate a synergistic effect on drawing pharma professional's attention in Japan by being held in parallel with other events. Pharmatec is an intimate exhibition for leading designers, manufacturers and suppliers:
Medtec Japan is the annual event where a visitor can meet the key design and manufacturing engineers of medical devices in Japan in one place at one time. Its focus is on allowing suppliers able to provide technology suitable for use in the manufacture of medical devices to meet with key design and manufacturing personnel from Japan based medical OEM's, with 76 per cent of visitors originating from medical device manufacturers.
The visitors' profile include CEOs & top executives, purchase executive, manufacturing engineers of pharmaceutical companies, R&D professionals, pharma machinery suppliers & distributors, pharma consultants, scientists and government experts.
The Pharmaceutical Export Promotion Council of India (Pharmexcil) will be organising the ‘India Pavilion’ at CPhI Japan. The global events like CPhI have enabled the Indian firms to showcase their innovations in drug development and have attracted the attention of many big global firms.
Presently, India is the country targeting the Japanese generics market most vigorously. Aided by a free trade agreement with Japan, which makes it easier to form business alliances with local firms, Indian bulk drug makers are looking to give a stronger focus on the Japanese market. Furthermore, India’s growing respect and legal/regulatory framework are making the country able to maintain a large basket of high quality affordable generics with assured safety and efficacy.
CPhI Japan showcases the rapidly progressing scenario of the pharmaceutical industry of Japan. Alongside Japanese companies a large number of international companies will be providing a global overview of this sector with new innovations and research techniques that are already on or in the anvil. As Asia's leading pharma industry and the world's second largest market, Japan is the right country to find the latest technologies and innovative products.